The emerging therapeutic role of probiotics in inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 4, Issue 9, 2008, Pages 634-640

  Chandler, Matthew ^c   Wollins, Eric ^c   Toles, Anastasia ^a   Borum, Marie ^a   Doman, David B ^a,b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c George Washington University of Medicine ^*

Author keywords

Crohn's disease; Inflammatory bowel disease; Pouchitis; Probiotics; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; CIPROFLOXACIN; CORTICOSTEROID; MESALAZINE; METRONIDAZOLE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; RIFAXIMIN; VSL3;

BACTEROIDES; BIFIDOBACTERIACEAE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HELICOBACTER PYLORI; HUMAN; ILEITIS; LACTOBACILLUS; MONOTHERAPY; REVIEW; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS;

EID: 53849146401     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Sartor RB. Kirsner's Inflammatory Bowel Disease. 6th ed. Edinburgh: Elsevier; 2003:128-162.
2. Biancone L, Monteleone I, Del Vecchio Blanco G, Vavassori P, Pallone F. Resident bacterial flora and immune system. Dig Liver Dis. 2002;34(suppl 2):S37-S43.
3. Jones J, Foxx-Orenstein A. The role of probiotics in inflammatory bowel disease. Dig Dis Sci. 2007;52:607-611.
4. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
5. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996;38:365-375-
6. Sartor B. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotic, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-1633.
7. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993-1000.
8. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohns disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol. 2003;15:627-634.
9. Cario E. Bacterial interaction with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut. 2005;54:1182-1193.
10. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev. 2005;206:277-295.
11. Sartor RB. Role of commensal enteric bacteria in the pathogenesis of immune-mediated intestinal inflammation: lessons from animal models and implications for translational research. J Pediatr Gastroenterol Nutr. 2005;40(suppl 1):S30-S31.
12. Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut. 2007;56:669-675.
13. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:106-111.
14. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol. 2006;55:1141-1149.
15. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains from isolated patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:45-56.
16. Floch MH, Moussa K. Probiotics and dietary fiber: the clinical coming of age of intestinal microecology. J Clin Gastroenterol. 1998;27:99-100.
17. Floch MH. Soluble dietary fiber and short-chain fatty acids: an advance in understanding the human bacterial flora. Am J Gastroenterol. 1990;85:1313-1314.
18. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126:1358-1373.
19. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277:50959-50965.
20. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
21. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of Bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
22. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-1574.
23. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia cols Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
24. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet. 1999;354:635-639.
25. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
26. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, et al. Randomized placebo-controlled trial assessing the effect of Bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-1141.
27. Roberfroid M. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr. 1998;80:S197-S202.
28. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut. 2005;54:242-249.
29. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis and treatment. Gastroenterology. 1994;107:1856-1860.
30. Ruseler-van Embden JG, Schouten WR, van Lieshout. Pouchitis: result of microbial imbalance? Gut. 1994;35:658-664.
31. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
32. Nasmyth DG, Godwin PG, Dixon MF, Williams NS, Johnston D. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology. 1989;96:817-824.
33. Sagar PM, Holdsworth PJ, Godwin PG, Quirke P, Smith AN, Johnston D. Comparison of triplicated (S) and quadruplicated (W) pelvic ileal reservoirs. Studies on manovolumetry, fecal bacteriology, fecal volatile fatty acids, mucosal morphology and functions results. Gastroenterology. 1992;102:520-528.
34. Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of dysplasia in long-term ileal pouches with chronic pouchitis. Gastroenterology. 2001;121:275-281.
35. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
36. Gionchetti P, Rizzello F, Helwig U. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
37. Gosselink MP, Schotiten W, van Lieshout L. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47:876-884.
38. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-515.
39. Laake KO, Bjorneklett A, Aamodt G, Aabakken L, Jacobsen M, et al. Outcomes of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal pouch-analanastomosis in ulcerative colitis. Scand J Gastroenterol. 2005;40:43-51.
40. Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, et al. Recommendations for probiotic use. J Clin Gastroenterol. 2006;40:275-278.
41. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease wirh special respect to chronic diarrhea - a pilot study. Z Gastroenterol. 1993;31:129-134.
42. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, et al. Expression of cytokines, inducible nitric oxide synthase and matrix metalloproteinases in pouchits: effects of probiotic treatment. Am J Gastroenterol. 2001;96:2691-2699.
43. Schultz M, Linde HJ, Lehn N, Zimmermann K, Grossmann J, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG (L. GG) in healthy volunteers. J Dairy Res. 2003;70:165-173.
44. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5.
45. Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22:1199-1204.
46. Doman DB, Goldberg HJ, Golding MI. "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. Am J Gastroenterol. 2008;103:251-252.
47. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-658.
48. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464.
49. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-963.
50. Marteau P, Lepage P, Mangin I, Suau A, Doré J, et al. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(suppl 4): 18-23.
51. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-1621.
52. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856-861.
53. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology. 2000;118:A781.
54. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomized controlled trial with Lactobacillus GG. Gut. 2002;51:405-409.
55. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842-847.
56. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after Ileo-caecal resection. Inflamm Bowel Dis. 2007;13:135-142.
57. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut. 2004;53:694-700.
58. Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007;150:531-538.
59. Steidler L, Neirynck S. In situ delivery of therapeutic proteins by recombinant Lactococcus lactis. J Microbiol. 2003;41:63-72.
60. Braat H, Rottiers P, Hommes D, Huyghebaert N, Remaut E, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754-769.
61. Shanahan F. Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr. 2002;88(suppl 1):S5-9.